Analysts Set IQVIA Holdings Inc. (NYSE:IQV) Target Price at $241.88

IQVIA Holdings Inc. (NYSE:IQV) has been assigned a consensus rating of “Moderate Buy” from the seventeen research firms that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $241.8824.

A number of analysts have recently commented on the company. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday. TD Cowen raised their price objective on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Morgan Stanley reiterated an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Stifel Nicolaus upped their price target on shares of IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Finally, Royal Bank Of Canada raised their price target on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th.

Insider Buying and Selling at IQVIA

In related news, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. This trade represents a 15.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.70% of the stock is owned by company insiders.

Institutional Trading of IQVIA

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Apella Capital LLC boosted its position in shares of IQVIA by 5.1% during the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock valued at $211,000 after buying an additional 58 shares during the last quarter. Quadrant Capital Group LLC raised its position in IQVIA by 1.3% in the 4th quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock worth $1,080,000 after buying an additional 60 shares during the last quarter. Private Advisor Group LLC lifted its stake in IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after acquiring an additional 63 shares during the period. Brookstone Capital Management boosted its holdings in shares of IQVIA by 2.2% during the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after acquiring an additional 63 shares during the last quarter. Finally, Breakwater Capital Group raised its holdings in shares of IQVIA by 3.2% during the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after purchasing an additional 64 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 0.7%

Shares of IQV opened at $233.37 on Thursday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA has a 52 week low of $154.50 and a 52 week high of $251.36. The stock has a market capitalization of $38.41 billion, a price-to-earnings ratio of 28.95, a PEG ratio of 1.99 and a beta of 1.18. The stock has a fifty day moving average of $196.05 and a 200-day moving average of $186.76.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the previous year, the company posted $2.81 EPS. IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, sell-side analysts anticipate that IQVIA will post 11.61 earnings per share for the current fiscal year.

IQVIA announced that its board has authorized a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.